<DOC>
	<DOC>NCT01620749</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.</brief_summary>
	<brief_title>Of 18F MEL050 Using PET/CT in Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Written informed consent obtained prior to any protocolspecific procedures Male and female patients with histologically confirmed melanoma At least one site of metastatic disease, as demonstrated on the prestudy 18F FDG PET/CT scan performed as part of routine clinical care Age &gt;/= 18 years Life expectancy &gt;/=3 months ECOG performance score of 02 Pregnant or breastfeeding females Systemic antimelanoma therapy within the 2 weeks prior to the prestudy 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan Patients whose clinical care may be compromised because of the delay resulting from performance of the 18F MEL050 PET/CT scan Patients whose only metastatic lesion is in the Central Nervous System Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study Patients unwilling or unable to comply with protocol and patients with a history of non compliance or inability to grant informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>melanoma metastatic diagnosis</keyword>
</DOC>